SEC Form 4 · accession 0000905148-26-002811
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dean L Schorno
Officer — EVP & Chief Financial Officer
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 6:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2026 | M | 1,200 | $18.70 | A | 77,537 | D | |
| Common StockF1 | Jun 1, 2026 | M | 2,181 | $12.70 | A | 79,718 | D | |
| Common Stock | Jun 1, 2026 | F | 928 | $29.86 | D | 78,790 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $18.70 | Jun 1, 2026 | M | 1,200 | D | — | Jan 26, 2033 | Common Stock | 1,200 | 9,632 | D |
| Employee Stock Option (right to buy)F1,F3 | $12.70 | Jun 1, 2026 | M | 2,181 | D | — | Jan 23, 2034 | Common Stock | 2,181 | 13,518 | D |
Explanation of responses
- F1These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
- F2The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.
- F3The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period.